We previously reported the protection of hematopoietic cells from methotrexate (MTX) toxicity using an N2-based double copy vector containing serine 31 (S31)-mutated dihydrofolate reductase (DHFR) (DC/SV6S31). To examine whether the use of SFG-based dicistronic vectors will lead to improvement in gene transfer over the DC/SV6 vector, we compared the protection provided by MTX to NIH3T3 cells and hematopoietic progenitor cells infected with these retroviral constructs containing the S31 variant DHFR cDNA. In NIH3T3 cells, the 50% effective dose values of MTX conferred by the SFG vector were 8-fold higher than those obtained with the DC/SV6 vector. DHFR mRNA levels were 22-fold and 38-fold higher than that seen for the DC/SV6 vector according to Northern blot and real-time polymerase chain reaction analysis, respectively. However, DHFR protein expression and DHFR enzyme activity were only 1.5-fold and 2-fold higher in the SFG vector, respectively, indicating that the mRNA from the SFG vector is translated less efficiently than the mRNA generated from the DC/SV6 vector. Furthermore, the degree of MTX protection conferred by each vector in both mouse and human hematopoietic cells was the same. These results indicate that the in vitro transduction efficiency and transgene expression of human DHFR in hematopoietic progenitor cells is equally conferred by both vectors. Cancer Gene Therapy (2000) 7, 910 -919
I n the field of hematopoietic stem cell gene transfer, retroviral vectors have been a major vehicle for stable proviral integration into the host genome. These vectors have been studied extensively, and their efficiency, safety, and feasibility for clinical use have been tested. 1 However, when retroviral vectors are used, efficient gene transfer is limited to dividing cells that express the viral envelope glycoprotein receptors. Newer generations of retroviral vectors have been produced and tested to achieve improved gene transfer efficiency and expression. We previously used an N2-based double copy vector carrying the serine 31 (S31) mutant human dihydrofolate reductase (DHFR) cDNA (DC/SV6S31) in vitro, and in the in vivo mouse model, to generate methotrexate (MTX) resistance in hematopoietic progenitor cells. [2] [3] [4] More recently, the availability of an SFG-based dicistronic vector 5 containing the myeloproliferative sarcoma virus (MPSV) enhancer/promoter sequence in the U3 region of the 3Ј-long terminal repeat (LTR) enabled us to compare this vector with the double copy vector for gene transfer efficiency and expression of the transgene. The double copy vector has a transcription unit under the control of an inserted internal promoter (simian virus 40 (SV40)) control region in the U3 region within the 3ЈLTR; this unit is reverse-transcribed and incorporated in both LTRs generated in the target cell. Consequently, this inserted transcription unit (S31 DHFR in our case) in the 3ЈU3 region is duplicated in the target cell and creates a double copy in the target cell. 6 The SFG-based dicistronic vector used has an internal ribosomal entry site (IRES) that allows transgenes to be expressed under LTR transcriptional control only. 5, 7 In this study, we compared the resistance to MTX conferred by DC/SV6S31 and SFGS31 retroviral constructs in NIH3T3 cells and in mouse and human hematopoietic progenitor cells.
MATERIALS AND METHODS

Cells
NIH3T3 cells were cultured in Dulbecco's modified Eagle-high glucose (with 4.5 g/L of glucose) media with 10% fetal bovine sera (FBS). The amphotropic viral packaging cell line GPenvAM12 has been described previously. 8 
Retrovirus constructs
The N2-based Moloney murine leukemia virus vector DC/ SV6S31 was constructed as described previously. 9 This vector contains a SV40 promoter and S31 DHFR cDNA cloned in the 3ЈLTR. The neomycin phosphotransferase (neo) gene is transcribed by the viral LTR promoter. Thus, upon infection of target cells, this expression unit is duplicated in the 5ЈLTR to form a double copy structure. 6 Figure 1a shows this construct. The SFG-based dicistronic retroviral vector containing mutant DHFR cDNA (S31) also contained the IRES of encephalomyocarditis virus and the neo gene. 5 This vector has a chimeric 3ЈLTR that contains a MPSV promoter/enhancer (Fig 1b) .
Retrovirus producer cell lines
The retrovirus vector constructs DC/SV6S31 and SFGS31 were transfected into the GP-AM12 packaging cell line using a N- [1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsulfate transfection kit (Boehringer Mannheim, Indianapolis, Ind). Transfected cells were selected with 750 g/mL G418 for 14 days. The G418-resistant colonies were isolated by ring-cloning and expanded into producer cell lines. Titers of these producer cell lines were measured using NIH3T3 cells as targets, and the highest titer colonies were used in subsequent experiments. The titer of these colonies was ϳ5 ϫ 10 5 colonyforming units (CFU)/mL for DC/SV6S31 and 1 ϫ 10 6 CFU/mL for SFGS31. Producer cells were replated in 100-mm plates and grown to 80% confluency; next, medium was changed to Dulbecco's modified Eagle-high glucose with 10% FBS. On the following day, the supernatant was collected and centrifuged at 1300 ϫ g for 20 minutes to remove cell debris; the top layer of supernatant was carefully aspirated and stored frozen at Ϫ70°C until use. Helper virus production was monitored with vector rescue assays. 10 Protection of cells infected with retroviral vectors containing mutated DHFR (S31) to MTX NIH3T3 cells were exposed to supernatants containing either the DC/SV6 S31 construct or the SFG S31 construct for 3 hours, in the presence of 8 g/mL polybrene. The supernatant volume to cell ratio was adjusted to achieve a multiplicity of infection (MOI) of 0.1 for each of these infections. After 3 hours, fresh medium was added to dilute the supernatant. Medium was changed at 24 hours, and cells were incubated with 20 nM trimetrexate for 3 days. This concentration of trimetrexate is 100% lethal to noninfected NIH3T3 cells but is not inhibitory to infected cells. Also, this 3-day selection does not change the 50% effective dose (ED 50 ) to MTX of infected cells. 9 After the 3-day selection, cells were plated in 96-well plates (400 cells/well) and subsequently exposed to increasing doses of MTX 24 hours later. After 5 days of exposure to MTX, 50 mL of sodium 3Ј-{1-[(phenylamino)-carbonyl]-3,4-tetrazolium}-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate, at a concentration of 1 mg/mL, was added together with phenazine methosulfate to measure cytotoxicity. 11 After a 4-hour incubation at 37°C, the optical density at 450 nm was measured using a 96-well plate reader. Absorbance was plotted with wells without drug (with cells) as 100% and wells without cells as 0%.
Southern blotting
NIH3T3 cells were harvested at late log phase. Cells were lysed in 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid (pH 8.0), 50 mM tris(hydroxymethyl)aminomethane (pH 8.0), 1% sodium dodecyl sulfate (SDS), and 0.6 mg/mL proteinase K overnight at 56°C. Genomic DNA was isolated using phenol/ chloroform extraction and ethanol precipitation. A total of 15 g of DNA per sample were digested with NheI, which releases a 1.1-kb fragment from the DC/SV6S31 cDNA and a 4.0-kb fragment from SFGS31. After gel electrophoresis and transfer to a nitrocellulose membrane (Optitran; Schleicher & Schuell, Keene, NH), the membrane was dried, ultraviolet cross-linked, and hybridized with a human DHFR probe labeled with [ 32 P]deoxycytidine triphosphate (dCTP). 12 After a vigorous wash with 1ϫ standard saline citrate and 0.1% SDS at room temperature, followed by washing at 60°C for 30 minutes to decrease the nonspecific hybridization to the mouse DHFR, the blot was visualized by autoradiography and quantitated with the Fuji Mac bas program (Fuji, Tokyo, Japan).
Northern blotting
Total cellular RNA was extracted according to the manufacturer's instructions using the Ultraspec RNA extraction reagent (Biotecx, Houston, Tex). A total of 15 g of RNA per sample was electrophoresed in agarose gels with 4-morpholinepropanesulfonic acid buffer and then transferred to nitrocellulose filters, dried, ultraviolet cross-linked, and hybridized to 32 P-labeled human DHFR or 36B4 acidic ribosomal phosphoprotein probes. 13 The blots were visualized by autoradiography and quantitated with the Fuji Mac bas program.
Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
The quantitation of mRNA levels was also carried out using a real-time fluorescence detection method as described previously.
14 After RNA isolation, cDNA was prepared from each sample as described previously. 15 The DHFR cDNA was PCR-amplified using an oligonucleotide probe with a 5Ј fluorescent reporter dye (5Ј,6-carboxyfluorescein) and quencher dye (3Ј,6-carboxy-tetramethylrhodamine). The 5Ј to 3Ј nuclease activity of Taq DNA polymerase cleaved the probe and released the reporter, whose fluorescence could be detected by the laser detector of the Applied Biosystems International Prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, Calif). The PCR amplification was performed using a 96-well optical plate tray and caps with a 25-L final reaction mixture consisting of 1400 nM each primer; 400 nM probe; 5 U of Ampli-Taq Gold; 200 M each of deoxyadenosine triphosphate, dCTP, and deoxyguanosine triphosphate; 400 M deoxyuridine triphosphate; 5.5 mM MgCl 2 ; 1 U of AmpErase uracil N-glycosylase; and 1ϫ TaqMan buffer A containing a reference dye at 50°C for 2 minutes and at 95°C for 10 minutes, followed by 42 cycles at 95°C for 15 seconds and at 60°C for 1 minute. The primer and probe sequences are listed below. In all cases, the first primer is the forward PCR primer, the second primer is the TaqMan probe, and the third primer is the reverse PCR primer. Internal control was measured by standardized ribosomal RNA sequence primers and TaqMan purchased from Perkin-Elmer. The DHFR primer and probe sequences are as follows: (a) GTCCTCCCGCTGCTGTCAT, (b) TTGGTTCGCTAAACTGCATCGTCGC, and (c) ATGC-CCATGTTCTGGGACAC.
Western blotting
Protein lysates were prepared from cells transduced by DC/ SV6S31, SFGS31, mock-transduced cells, and DG44 cells (a DHFR Ϫ/Ϫ cell line, as a DHFR negative control). The cells were lysed in the buffer described previously. 16 After 20 minutes of incubation on ice and centrifugation at 15,000 ϫ g for 20 minutes, the supernatant fluid was recovered. The protein concentration was determined by the Bio-Rad protein determination reagent (Bio-Rad, Hercules, Calif) according to the manufacturer's instructions using bovine serum albumin as a standard. Lysate containing 25 g of protein was used for electrophoresis on 12.5% SDS-polyacrylamide gel electrophoresis. After transfer to a nitrocellulose membrane, the membrane was incubated for 2 hours with anti-human DHFR antibody (Ab), a rabbit polyclonal anti-serum raised against recombinantly expressed human DHFR protein, followed by goat anti-rabbit secondary Ab (Santa Cruz Biotechnology, Santa Cruz, Calif). The protein bands were visualized on x-ray film using the enhanced chemiluminescence reagent from Amersham (Arlington Heights, Ill). For the loading control, the same membrane was stripped and incubated for 2 hours with anti-human ␤-actin Ab (Santa Cruz Biotechnology), followed by anti-mouse secondary Ab (Santa Cruz Biotechnology). The protein bands were visualized as described above.
The intensity of the bands was measured with a Bio-Rad GS-710 Calibrated Imaging Densitometer; for each vector DHFR density was divided by the corresponding control band density.
Dot blot hybridization
DNA from each cell line was denatured with 0.3N NaOH, 2 M ammonium acetate was added, and DNA was blotted onto nitrocellulose filters and hybridized with a [ 32 P]dCTP-labeled human DHFR cDNA probe as described previously. 17 The same membrane was stripped and used as a DNA loading control by hybridizing with a [ 32 P]dCTP-labeled ␥-actin cDNA probe. The blot was visualized by autoradiography and quantitated with a ␤ scope 603 blot analyzer (Betagen, Waltham, Mass).
DHFR enzyme assay
Enzyme activity was determined spectrophotometrically using NIH3T3 cells transduced by mock, DC/SV6S31, and SFGS31 vectors, which were used in the experiments described above.
Crude extracts were prepared from cell pellets as described previously. 18 Supernatant was collected, and the protein concentration was determined with Bio-Rad protein determination reagent (Bio-Rad) according to the manufacturer's instructions, using bovine serum albumin as a standard. Conversion of reduced nicotinamide-adenine dinucleotide phosphate and dihydrofolate to reduced nicotinamide-adenine dinucleotide phosphate ϩ and 5,6,7,8-tetrahydrofolate is followed at 340 nm. 19 The specific activity was calculated and described as units per milliliter per milligram.
Mouse bone marrow granulocyte-macrophage CFU (GM-CFU) assays CBA/DB2Fl male mice were treated with a single intravenous dose of 5-fluorouracil (150 mg/kg). After 4 days, bone marrow cells were harvested from femurs and tibias and resuspended in Iscove's modified Dulbecco's medium (IMDM) with 20% FBS. Retroviral infection was carried out by the coculture method. In brief, bone marrow cells in IMDM and 10% FBS were pipetted into 100-mm plates that were ϳ80% confluent with viral producer cells; cells were irradiated at 1500 cGy on the day of coculture. The target bone marrow cell to producer cell ratio was ϳ1:1 for both DC/SV6S31 and SFGS31. After coculture for 48 hours at 37°C, bone marrow cells were added in 10 ϫ 35-mm plates to 2 mL of semisolid medium containing 1% methylcellulose, thymidine phosphorylase-treated 20% FBS, 10% WEIHI-3B conditioning medium, 1% NaHCO 3, 1% sodium pyruvate, 1 M ␤-mercaptoethanol, 100 U/mL penicillin, 100 g/mL streptomycin, 1% essential amino acids, 1.5% nonessential amino acids, and 0.5% vitamin C. The cells were incubated with increasing doses of MTX continuously. The plates were kept at 37°C in a 5% CO 2 incubator, and colonies of Ͼ50 cells were scored after 12 days. 4 Human peripheral blood progenitor cell transduction and GM-CFU assays
A CD34
ϩ enriched population of cells from donors undergoing granulocyte colony-stimulating factor-mobilized leukapheresis was obtained using a Ceprate SC stem cell concentrator (CellPro, Bothell, Wash). CD34 ϩ enriched cells were stored at Ϫ80°C until use. Thawed cells were centrifuged; resuspended in fresh medium containing IMDM, 20% FBS, 100 ng/mL stem cell factor (kit-ligand) (Kirin Pharmaceuticals, Tokyo, Japan), 100 U/mL human interleukin-6 (IL-6) (Sigma, St. Louis), and l00 ng/mL human IL-3 (Sigma, St. Louis, Mo); and preincubated for 48 hours at 37°C in a 5% CO 2 incubator. Transduction was done using viral supernatant with cytokine stimulation. Cells were resuspended with 1-2 mL of viral supernatant to obtain an MOI of 1, added with the same concentration of cytokines as described above, and the cell suspension was added to retronectin-coated Falcon tubes according to the manufacturer's instructions (Takara-Shuzo, Tokyo, Japan). The cells were centrifuged at 1500 rpm for 30 minutes at room temperature, and another 1-2 mL of viral supernatant with the same concentration of cytokines was added 2 hours later and incubated for another 22 hours. Cells were harvested, counted, and plated on a 10 ϫ 35-mm dish with 2 mL of semisolid medium containing 1% methylcellulose, 20% thymidine phosphorylase-treated FBS, 100 ng/mL stem cell factor, 100 U/mL human IL-6, l00 ng/mL human IL-3, 1% NaHCO 3 , 1% sodium pyruvate, 1 M ␤-mercaptoethanol, 100 u/mL penicillin, 100 g/mL streptomycin, and 1% L-glutamine. MTX was added at various doses, and the cells were incubated at 37°C in 5% CO 2 for 14 days, after which colonies of Ͼ50 cells were scored. The experiment was duplicated.
Detection of proviral DNA in GM-CFU colonies by PCR amplification
Human CD34
ϩ enriched cell GM-CFU colonies (5 colonies, ϳ1000 cells) from SFGS31, DC/SV3S31, and mock vector transfections were collected in Eppendorf tubes containing 50 -100 L of Perkin-Elmer PCR buffer (Roche Molecular Systems, Branchburg, NJ), and genomic DNA was extracted after adding 10 g of proteinase K followed by 3 hours of incubation at 58°C. A total of 1 L of genomic DNA was used for each PCR. Colonies transduced with SFGS31 and DC/ SV6S31 as well as with mock vectors were evaluated by PCR amplification of a 430-bp fragment of the Neo cDNA from genomic DNA using the following primers: Neo3000, 5Ј-CAGCTGTGCTCGACGTTGTC; Neo3430, 5Ј-TATGTCCT-GATAGCGGTCCG. The PCR conditions used in this experiment are as follows: 94°C for 5 minutes in the denaturing period, then cycles consisting of 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1 minute for 40 cycles. The PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide staining.
RESULTS
Protection of NIH3T3 cells and virally infected cells to MTX
To compare the ability of S31 DHFR cDNA in the two different vectors to generate MTX resistance, GPenvAM12-SFG-IRES-S31, GP-envAM12-DC/SV6S31, and mock-transduced NIH3T3 cells were exposed to varying doses of MTX for 5 days. The ED 50 of MTX in cells infected with the DC/SV6S31 and SFGS31 vectors increased 5-fold and 40-fold, respectively, compared with the nontransduced NIH3T3 cells (Fig 2) . To ensure a single copy integration of proviral sequences to each infected cell, an MOI of 0.1 was used for each retroviral construct. Southern blot analysis was performed to compare the average copy numbers of the proviral sequences in the transduced cell lines. A 1.1-kb DHFR band was detected in the DC/SV6S31-transduced cell line, and a 4.0-kb DHFR band was detected in the SFG vector-transduced cells, corresponding to the size of the digested cDNA by NheI restriction sites (Fig 3) . Based on the analysis of the intensity using a densitometer, the DC/SV6S31 band was 2-fold greater than that of the SFGS31 band, indicating that DC/SV6S31-transduced cells contained a 2-fold increase in gene copies per cell. Dot blot analysis was performed to further confirm the gene copy number in transduced cells. Human DHFRprobed, transduced cells were analyzed for the relative DHFR radioactivity ratio. The mock-transduced NIH3T3 cell radioactivity was measured and calculated as the base line. The calculated ratio was 1.0 -1.9 for SFGS31 and DC/SV6S31, respectively, and confirmed that one proviral gene is present per transduced cell.
Northern blot analysis
Despite the finding that viral DC/SV6S31 integration into DNA resulted in two copies of additional mutated DHFR per cell, while SFGS31 integration gave rise to only one additional copy of DHFR, SFGS31 DHFR mRNA expression was 22-fold higher in cells infected with the SFG vector compared with the DC/SV6S31 vector. Thus, in NIH3T3 cells, DHFR mRNA is transcribed with a higher efficiency from the integrated SFG vector compared with the DC/SV6 vector (Fig 4) .
Quantitative RT-PCR analysis
To confirm the Northern blot data and to obtain a more quantitative comparison, quantitative RT-PCR analysis was performed. The relative expression levels of human DHFR in three cell lines (mock-, DC/SV6S31-, and SFGS31-transduced NIH3T3 cell lines) are shown in Figures 5 and 6 . The relative expression levels are displayed as the ratio between human DHFR and the reference gene, ribosomal RNA, to correct for variations in the amounts of RNA. The ratio of RNA detected was 1:35 Ϯ 9 for DC/SV6S31 and SFGS31, respectively ( Fig  6) . This result was consistent with the Northern blot analysis as described above. 
Western blot analysis
Western blot analysis was performed to compare the level of DHFR protein expressed in NIH3T3 cells transduced with the two vectors (Fig 7) . A rabbit monoclonal Ab raised to human DHFR that recognized human DHFR and not mouse DHFR was used. No expression of human DHFR was observed in either the nontransduced NIH3T3 cell line or the hamster DG44 cell line, which lacks the DHFR gene. A serial dilution of recombinant, purified, human DHFR protein was also blotted to estimate the amount of DHFR protein in the transduced cell lines, and as a positive control. The expression level of DHFR and a ␤-actin loading control was measured by densitometry. The ratio of DHFR/␤-actin was 1 and 1.5 for the DC/SV6 and SFG vectortransduced cells, respectively.
DHFR enzyme assay
Crude lysates from mock-, DC/SV6S31-, and SFGS31-transduced NIH3T3 cells were used for DHFR enzyme assay (see Materials and Methods). The specific activities were 0.08, 0.11, and 0.22 U/mL/mg for mock-, DC/ SV6S31-, and SFGS31-transduced cells, respectively. The enzyme activity of mock-transduced cells is the baseline mouse endogenous DHFR activity. When the baseline activity level is subtracted from the activity of the transduced cells, the SFGS31 vector showed an ϳ5-fold increase in enzyme activity compared with the DC/SV6S31 vector.
Mouse bone marrow GM-CFU assay After 12 days of culture in the presence of MTX, mouse bone marrow cells infected with SFGS31 showed a similar level of protection against MTX cytotoxicity compared with cells transduced with the DC/SV6S31 construct, as measured by GM-CFU assay. As there was no preselection process, the efficiency of transduction by the retroviral constructs in marrow progenitors was not as high as with NIH3T3 cells (Fig 8) . Two separate experiments were conducted, and the data shown are a mean value of these experiments. The data were analyzed as repeated measures count data (the number of colonies surviving are the counts and the experiments are the repeated measurements) via the Poisson regression model. We found that there is a significant difference between the mock-and vector-transduced resistant colonies (P Յ .0001); however, there is no significant difference after MTX treatment after infection with either DC/SV6S31 or SFGS31 (P Ͼ .1).
Human peripheral blood cell CD34
ϩ enriched cell transduction CD34 ϩ enriched cells were exposed to viral supernatant twice in the fibronectin-coated Falcon tubes in combination with centrifugation (see Materials and Methods). After 14 days of culture in the presence of MTX, approximately the same number of GM-CFU colonies from human CD34 ϩ enriched cells infected with SFGS31 were observed compared with cells infected with the DC/SV6S31 construct (Fig 9) . The experiment was repeated, and the mean values are shown. A logistic regression model was applied to analyze the data. A significant difference in transduction by both vectors is Figure 8 . Protection of mouse bone marrow from MTX toxicity was determined by GM-CFU assay. Mouse bone marrow cells were infected by coculture with producer cell lines (o, mock; Ⅺ, DCSV6S31; s, SFGS31). Colony numbers were counted and also shown as percentages, with colony numbers without MTX as 100%. Two experiments were conducted, the mean value is shown in the graph. Data were analyzed by the Poisson regression model. There is a significant difference between colonies formed in the mock-and vector-transduced progenitors (P ϭ .0001); however, there is no significant difference between DC/SV6S31-and SFGS31-transduced progenitors (P ϭ .11 and .29 for both experiments).
seen for the mock-and vector-transduced resistant clones (P ϭ .0001), but there is no significant difference in the number of colonies surviving MTX treatment between DC/SV6 and SFG vector-transduced progenitors (P ϭ .237).
Proviral integration into human progenitor cells Integration of the virus into human CD34
ϩ enriched cells was detected by PCR amplification of the neo gene fragment (primers as described above) in DNA isolated from day 14 GM-CFU pooled colonies (five colonies). A Neo cDNA band with a size of 430 bp was observed in both the DC/SV631 or SFGS31 vector-transduced colonies, whereas no amplification product was seen in mock-transduced colonies (Fig 10) .
DISCUSSION
We compared the efficiency of two Moloney murine leukemia virus-based vectors, an N2-based double copy vector, and an MFG-based SFG vector by analyzing the level of protection from the cytotoxicity of NIH3T3 cells and GM-CFU colonies from transduced mouse bone marrow and human peripheral blood cell CD34 ϩ en- Figure 9 . Protection of human CD34 ϩ enriched cells from MTX toxicity as determined by GM-CFU assay. CD34 ϩ enriched cells were infected by supernatants (o, mock; Ⅺ, DC/SV6S31; s, SFGS31) with fibronectin-coated Falcon tubes. Colony numbers are also shown as percentages, with colony numbers without MTX as 100%. The experiment was duplicated and the mean value is shown in the graph. Data were analyzed by a logistic regression model. There is a significant difference between colonies formed in the mock-and vector-transduced progenitors (P ϭ .0001); however, there is no significant difference between DC/SV6S31-and SFGS31-transduced progenitors (P ϭ .237). Figure 10 . Detection of proviral integration into human progenitor cells by PCR amplification. Primers for neo were used as described in Materials and Methods. Five colonies from each group were pooled and analyzed as described in Materials and Methods. Lane 1, control using genomic DNA from mock-transduced GM-CFU colonies as a template. Lanes 2 and 3 show detection of the 430-bp Neo cDNA obtained by PCR amplification from GM-CFU colonies after human CD34 ϩ enriched cell transduction with SFGS31 and DC/SV6S31, respectively. Samples were run with a molecular weight marker as shown.
riched cells. To determine vector efficiency due to the different backbone structures of the vectors and not by differences in proviral copy numbers, we infected NIH3T3 cells with each viral supernatant at an MOI of 0.1 to assure that no more than one proviral gene copy was transduced per cell.
The SFG vector was designed for dual gene expression using a single transcription unit to avoid the potential problems that can occur with retroviral vectors containing internal promoters. 20, 21 The SFG vector also contains an MPSV promoter/enhancer sequence in the 3ЈLTR that may enhance expression of the transgene in target cells, especially in hematopoietic cells. The double copy vector was designed to eliminate or at least reduce the negative effects of the retroviral transcriptional unit by placing the gene of interest outside the retroviral transcriptional unit. 6 We observed an 8-fold difference (the ED 50 of DC/ SV6S31 and SFGS31 was increased 5-fold and 40-fold compared with mock) in protection from cytotoxicity of MTX between DC/SV6S31 and SFGS31 constructs in NIH3T3 cells. Northern blot analysis as well as quantitative RT-PCR showed a 22-to 38-fold difference in mRNA levels between DC/SV6S31 and SFGS31 (SFGS31 Ͼ DC/SV6S31). However, when Western blot analysis was performed using a human monoclonal DHFR Ab, the expression of human DHFR protein was increased only by 1.5-fold in SFGS31-transduced NIH3T3 cells compared with DC/SV6S31-transduced NIH3T3 cells. According to an enzyme assay, the difference between the cells transduced with the SFG construct and the cells transduced with the DC/SV6 construct was 5-fold when endogenous DHFR activity was subtracted from mock-transduced NIH3T3 cells. Thus, according to both Western blot analysis and enzyme analysis, the protein expression of DHFR was much less than expected, given the 22-to 38-fold difference in the level of DHFR mRNA.
The gap between the increased mRNA expression level and the protein expression level, or the enzyme activity in NIH3T3 cells transduced by DC/SV6S31 and SFGS31, may be due to the efficient transcription of MFG-based, SFG vector-containing cDNAs as described previously. 22 In addition, our results indicated that the mRNA produced by the DC/SV6 vector may be translated more efficiently than the mRNA generated by the SFG vector. It has been reported that mRNA translation efficiency is associated with the secondary structure of mRNA. 23 It is possible that the mRNA structure of SV40-DHFR sequences (for DC/SV6S31) contains a less complex secondary structure compared with the mRNA from the DHFR-IRES-Neo sequence (for SFGS31).
We reported previously that the double mutant, Phe22/Ser31 (F/S) cDNA conferred superior protection from MTX toxicity compared with the single mutant S31. 5 Thus, either the SFG vector or the DC/SV6 vector containing human mutated DHFR F/S may be of value in human gene transfer clinical studies. Further studies comparing the ability of these two retroviral constructs to confer long-term expression would be of interest.
